Abeona Therapeutics (ABEO) Common Equity (2010 - 2026)
Abeona Therapeutics (ABEO) posted quarterly Common Equity of $144.9 million for Q1 2026, up 250.13% year-over-year from $41.4 million in Q1 2025, and down 8.97% quarter-over-quarter from $159.2 million in Q4 2025.
Abeona Therapeutics (ABEO) Common Equity (2010 - 2026) Analysis & Trends
Abeona Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $144.9 million for Q1 2026.
- In Q1 2026, Common Equity rose 250.13% year-over-year to $144.9 million; the TTM figure through Mar 2026 stood at $144.9 million (up 250.13% YoY), while the FY2025 annual figure was $159.2 million, up 261.6% from the prior year.
- Common Equity for Q1 2026 stood at $144.9 million, down from $159.2 million in the prior quarter.
- The five-year high for Common Equity was $171.2 million in Q3 2025, with the low at -$8.9 million in Q1 2024.
- The 5-year median for Common Equity is $26.8 million (2022), against an average of $57.3 million.
- Peak annual rise in Common Equity reached 683.75% in 2024, while the deepest fall reached 147.39% in 2024.
- Abeona Therapeutics' Common Equity stood at $26.8 million in 2022, then slumped by 44.6% to $14.8 million in 2023, then soared by 196.99% to $44.0 million in 2024, then surged by 261.6% to $159.2 million in 2025, then dropped by 8.97% to $144.9 million in 2026.
- Business Quant data shows ABEO's Common Equity at $144.9 million in Q1 2026, $159.2 million in Q4 2025, and $171.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Abeona Therapeutics | 342.78 Mn | 195.96 Mn | 7.20 Mn | 128.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128.06 Mn |
| Mar 31, 2026 | 144.94 Mn |
| Dec 31, 2025 | 159.22 Mn |
| Sep 30, 2025 | 171.23 Mn |
| Jun 30, 2025 | 163.58 Mn |
| Mar 31, 2025 | 41.40 Mn |
| Dec 31, 2024 | 44.03 Mn |
| Sep 30, 2024 | 45.77 Mn |
| Jun 30, 2024 | 73.24 Mn |
| Mar 31, 2024 | -8.88 Mn |
| Dec 31, 2023 | 14.83 Mn |
| Sep 30, 2023 | 22.04 Mn |
| Jun 30, 2023 | 9.35 Mn |
| Mar 31, 2023 | 18.74 Mn |
| Dec 31, 2022 | 26.76 Mn |
| Sep 30, 2022 | 12.40 Mn |
| Jun 30, 2022 | 14.02 Mn |
| Mar 31, 2022 | 21.18 Mn |
| Dec 31, 2021 | 42.37 Mn |
| Sep 30, 2021 | 79.74 Mn |